For several years, Biotech-Industry has devoted itself to researching new, high-technology pharmaceutical products, in order to treat many types of wounds and burns:
Serious, acute and chronic traumatic wounds as well as haemorrhaging, etc.
The laboratory is launching on the market a range of Biotech-Industry products based on Chitosan succinate following 10 years of research and development, for the first sterile treatment of serious traumatic injuries and burns (haemostasis, sedation and cellular reconstruction) to be applied to all superficial and deep wounds.
Created in Luxembourg by the pharmaceutical Research and Development company Biotech-Industry.
Injectable DM filed with PCT
Research and Development
CE mark (Class III)
New Fill® for treating lipoatrophy.
Marketing in Europe, Russia and South America of DM New Fill®.
Transfer of the patent to the Aventis group.
Research and Development into the dermatological application of a heat-sensitive Chitosan gel. Université de Genève.
Transfer of the injectable Chitosan implant patent for treating cutaneous depressions of the face with Cutanéa (R&D patent from 2005 to 2007).
International filing of a PCT patent for a Chitosan succinate hydrogel.
Creation of KITO-KIT®, treatment of wounds and burns.
Development of the DM KITO-KIT®.
Final formulation, pre-clinical tests and clinical trials, regulatory update.
Filing of a patent:
Injectable DM class III non-crosslinked hyaluronic acid for controlled release.
ISO 9001 and 13485 certification of Biotech-Industry by SGS
CE mark KITO-KIT®
Registration and commercial launch of the KITO-KIT® in Europe, Asia, South America and the Middle East.